COVID-19 Vaccination in Korea: Past, Present, and the Way Forward
10.3346/jkms.2022.37.e351
- Author:
Eliel NHAM
1
;
Joon Young SONG
;
Ji Yun NOH
;
Hee Jin CHEONG
;
Woo Joo KIM
Author Information
1. Division of Infectious diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea
- Publication Type:Review Article
- From:Journal of Korean Medical Science
2022;37(47):e351-
- CountryRepublic of Korea
- Language:English
-
Abstract:
Since its first emergence in late 2019, severe acute respiratory syndrome coronavirus-2 has claimed more than 6.5 million lives worldwide and continues to infect hundreds of thousands of people daily. To combat this once-in-a-century disaster, several vaccines have been developed at unprecedented speeds. Novel vaccine platforms (messenger ribonucleic acid vaccines and adenoviral vector vaccines) have played a major role in the current pandemic. In Korea, six vaccines, including a domestically developed recombinant vaccine, have been approved. As in other countries, vaccines have been proven to be safe and highly effective in Korea. However, rare serious adverse events and breakthrough infections have undermined public trust in the vaccines, even while the benefits of vaccination far outweigh the risks. The rise of the omicron variant and the subsequent increase in excess mortality demonstrated that while vaccines are a key component of the pandemic response, it alone can fail without non-pharmaceutical interventions like masking and social distancing. The pandemic of coronavirus disease has revealed both the strengths and weaknesses of our healthcare system and pandemic preparedness. When the next pandemic arrives, improved risk communication and vaccine development should be prioritized. To enable timely vaccine development, it is essential to make strategic and sufficient investments in vaccine research and development.
